An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearanc...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-03-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | https://doi.org/10.1371/journal.pntd.0009294 |
id |
doaj-17857130e5214bf69a99373600823cb3 |
---|---|
record_format |
Article |
spelling |
doaj-17857130e5214bf69a99373600823cb32021-07-02T04:30:51ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352021-03-01153e000929410.1371/journal.pntd.0009294An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.Taniawati SupaliYenny DjuardiMichael ChristianElisa IskandarRahmat AlfianRoospita MaylasariYossi DestaniAdriani LomigaDominikus MingguDaphne LewJoshua BogusGary J WeilPeter U FischerImproved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearance of microfilariae (Mf) of the filarial parasite Wuchereria bancrofti from human blood. However, the triple drug combination has not been previously been evaluated for treatment of brugian filariasis, which accounts for about 10% of the global LF burden. This hospital-based clinical trial compared the safety and efficacy of IDA with that of the standard treatment (DEC plus albendazole, DA) in persons with Brugia timori infections on Sumba island, Indonesia. Fifty-five asymptomatic persons with B. timori Mf were treated with either a single oral dose of IDA (28 subjects) or with DEC plus albendazole (DA, 27 subjects). Participants were actively monitored for adverse events (AE) for two days after treatment by nurses and physicians who were masked regarding treatment assignments. Passive monitoring was performed by clinical teams that visited participant's home villages for an additional five days. Microfilaremia was assessed by membrane filtration of 1 ml night blood at baseline, at 24h and one year after treatment. IDA was more effective than DA for completely clearing Mf at 24 hours (25/28, 89% vs. 8/27, 30%, P < 0.001). By 12 months after treatment, only one of 27 IDA recipients had Mf in their blood (4%) vs. 10 of 25 (40%) in persons treated with DA (P = 0.002). Approximately 90% of participants had antibodies to recombinant filarial antigen BmR1 at baseline. Antibody prevalence decreased to approximately 30% in both treatment groups at 12 months. About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. This study showed that IDA was well-tolerated and significantly more effective for clearing B. timori Mf from the blood than DA. Larger studies should be performed to further assess the safety and efficacy of IDA as a mass drug administration regimen to eliminate brugian filariasis. Trial Registration: NCT02899936.https://doi.org/10.1371/journal.pntd.0009294 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Taniawati Supali Yenny Djuardi Michael Christian Elisa Iskandar Rahmat Alfian Roospita Maylasari Yossi Destani Adriani Lomiga Dominikus Minggu Daphne Lew Joshua Bogus Gary J Weil Peter U Fischer |
spellingShingle |
Taniawati Supali Yenny Djuardi Michael Christian Elisa Iskandar Rahmat Alfian Roospita Maylasari Yossi Destani Adriani Lomiga Dominikus Minggu Daphne Lew Joshua Bogus Gary J Weil Peter U Fischer An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. PLoS Neglected Tropical Diseases |
author_facet |
Taniawati Supali Yenny Djuardi Michael Christian Elisa Iskandar Rahmat Alfian Roospita Maylasari Yossi Destani Adriani Lomiga Dominikus Minggu Daphne Lew Joshua Bogus Gary J Weil Peter U Fischer |
author_sort |
Taniawati Supali |
title |
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. |
title_short |
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. |
title_full |
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. |
title_fullStr |
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. |
title_full_unstemmed |
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. |
title_sort |
open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in indonesia. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Neglected Tropical Diseases |
issn |
1935-2727 1935-2735 |
publishDate |
2021-03-01 |
description |
Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearance of microfilariae (Mf) of the filarial parasite Wuchereria bancrofti from human blood. However, the triple drug combination has not been previously been evaluated for treatment of brugian filariasis, which accounts for about 10% of the global LF burden. This hospital-based clinical trial compared the safety and efficacy of IDA with that of the standard treatment (DEC plus albendazole, DA) in persons with Brugia timori infections on Sumba island, Indonesia. Fifty-five asymptomatic persons with B. timori Mf were treated with either a single oral dose of IDA (28 subjects) or with DEC plus albendazole (DA, 27 subjects). Participants were actively monitored for adverse events (AE) for two days after treatment by nurses and physicians who were masked regarding treatment assignments. Passive monitoring was performed by clinical teams that visited participant's home villages for an additional five days. Microfilaremia was assessed by membrane filtration of 1 ml night blood at baseline, at 24h and one year after treatment. IDA was more effective than DA for completely clearing Mf at 24 hours (25/28, 89% vs. 8/27, 30%, P < 0.001). By 12 months after treatment, only one of 27 IDA recipients had Mf in their blood (4%) vs. 10 of 25 (40%) in persons treated with DA (P = 0.002). Approximately 90% of participants had antibodies to recombinant filarial antigen BmR1 at baseline. Antibody prevalence decreased to approximately 30% in both treatment groups at 12 months. About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. This study showed that IDA was well-tolerated and significantly more effective for clearing B. timori Mf from the blood than DA. Larger studies should be performed to further assess the safety and efficacy of IDA as a mass drug administration regimen to eliminate brugian filariasis. Trial Registration: NCT02899936. |
url |
https://doi.org/10.1371/journal.pntd.0009294 |
work_keys_str_mv |
AT taniawatisupali anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT yennydjuardi anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT michaelchristian anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT elisaiskandar anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT rahmatalfian anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT roospitamaylasari anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT yossidestani anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT adrianilomiga anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT dominikusminggu anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT daphnelew anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT joshuabogus anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT garyjweil anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT peterufischer anopenlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT taniawatisupali openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT yennydjuardi openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT michaelchristian openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT elisaiskandar openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT rahmatalfian openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT roospitamaylasari openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT yossidestani openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT adrianilomiga openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT dominikusminggu openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT daphnelew openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT joshuabogus openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT garyjweil openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia AT peterufischer openlabelrandomizedclinicaltrialtocomparethetolerabilityandefficacyofivermectinplusdiethylcarbamazineandalbendazolevsdiethylcarbamazineplusalbendazolefortreatmentofbrugianfilariasisinindonesia |
_version_ |
1721339990008397824 |